The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea.

Autor:	Nam, J. S., Kim, A. R., Yoon, J. C., Byun, Y., Kim, S. A., Kim, K. R., Cho, S., Seong, B. L., Ahn, C. W., Lee, J. M.
Předmět:	INFLUENZA prevention AGE distribution CHI-squared test COMPUTER software ENZYME-linked immunosorbent assay HOSPITALS IMMUNIZATION IMMUNOGLOBULINS TYPE 2 diabetes HEALTH outcome assessment RESEARCH funding STATISTICAL sampling T-test (Statistics) LOGISTIC regression analysis DATA analysis TREATMENT effectiveness INFLUENZA A virus H1N1 subtype
Zdroj:	Diabetic Medicine; Jul2011, Vol. 28 Issue 7, p815-817, 3p
Abstrakt:	Aims We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemicH1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. Methods Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA. Results Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range orwith longer duration of diabetes had a lower seroconversion rate. Conclusions Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text